FMC Corp Bets That One Painful Quarter Can Fix Its Sales Channel

Farmers around the world depend on a small group of chemical makers to keep insects, weeds and fungus away from their crops. One of the oldest of those suppliers just told investors that its third quarter went far worse than anyone expected. FMC Corporation (NYSE: FMC) is the Philadelphia agricultural sciences company behind a wide range of insecticides, herbicides, fungicides and biological products. It now expects revenue of between $65 million and $125 million for the three months that ended September 30th. Over the summer, it had guided to between $840 million and $900 million. 

The profit picture is even more striking. Adjusted EBITDA is a common measure of operating earnings before interest, taxes and noncash items such as depreciation. FMC expects it to land somewhere between a loss of $510 million and a loss of $565 million. Investors reacted quickly, and the stock fell as low as 41% in early trading before retracing somewhat. 

Most of the damage comes from a choice FMC made on purpose. The company says demand was weaker than planned. Distributors and retailers, which it calls channel customers, were still holding large amounts of FMC product they had bought at higher prices. When those shelves stay full, new orders dry up. Chief executive Pierre Brondeau said the company had chipped away at the problem for several quarters but concluded that “more comprehensive actions are necessary.” FMC will cut prices on select products already held by channel customers in Brazil, Argentina, the U.S. and Canada, and it is changing how it sells and prices products in the U.S. The estimated cost of those moves is between $625 million and $675 million. 

To see why that inventory became a problem, it helps to look at FMC’s best known product. Rynaxypyr is the brand name for an insecticide ingredient called chlorantraniliprole, and for years it was a major profit engine protected by patents. Those core patents have now expired in all major markets, and several related manufacturing patents lapsed in many key markets in December 2025. Cheaper generic versions have followed, and FMC has been lowering its own prices to compete. Product that distributors bought at older, higher prices is hard to move when growers can find cheaper alternatives. 

The company was not always this small. FMC was a member of the S&P 500 until March 2025, when S&P Dow Jones Indices moved it to the S&P SmallCap 600. Late in 2025, S&P Global Ratings cut its credit rating below investment grade and pointed to the loss of patent protection as a key reason. Earlier this year, the board began exploring strategic options, including a possible sale of the company. 

That review ended with a partner rather than a buyer. Tessenderlo Group NV (XBRU: TESB.BR) is a Belgian industrial group with its own agriculture business. On June 30th this year, it agreed to buy about 20% of FMC at $13.30 per share, roughly $403 million in total. The deal closed on September 23rd. Tessenderlo accepted a three-year lock-up, which means it cannot simply sell its shares during that period. FMC said it would use the money to pay down debt. Even before the closing, FMC shares were trading near $10, so the investment was already under water before today’s news. 

So which story is this? One reading is that FMC is clearing out years of overpriced inventory in a single painful quarter, so future sales reflect real demand rather than leftover stock. Another reading is that the price cuts show how much value generic competition has already taken out of the business, and that lower prices may be permanent. The company also warned that it may have to record a large noncash impairment charge. That is an accounting writedown reflecting a lower expected value for some of its intangible assets. 

The next clues arrive soon. FMC plans to report full third quarter results on October 29th and share its first look at 2027 and 2028 on a call the following day. Those numbers should show whether the price reset brings orders back. They should also show how the company intends to handle its debt and its dividend after a quarter like this one.